Cancer diagnostic
AssigneeThe Council of the Queensland Institute of Medical Research
InventorsRichard Lobb, Andreas Möller
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of cancer. More particularly, the invention relates to methods of diagnosing and treating cancer, including determining a cancer type thereof. These methods involve the detection of markers in an exosome sample of the subject.
Claims22
A method of diagnosing a cancer or recurrence of a cancer in a subject, said method including the step of determining an expression level of a plurality of markers in an exosome sample of the subject, wherein the markers are selected from the group consisting of VCAN, NID1, PTX3, and THBS1, and wherein the expression level of the plurality of markers indicates or correlates with a diagnosis or recurrence of the cancer.
A method of predicting and/or determining the responsiveness of a cancer to an anti-cancer treatment in a subject, said method including the step of determining an expression level of a plurality of markers in an exosome sample of the subject, wherein the markers are selected from the group consisting of VCAN, NID1, PTX3, and THBS1 and an altered or modulated expression level of the plurality of markers indicates or correlates with relatively increased or decreased responsiveness of the cancer to the anti-cancer treatment.
A diagnostic kit or test device for use in a method of diagnosing a cancer or recurrence of a cancer in a subject, said method including the step of determining an expressing level of a plurality of markers in an exosome sample of the subject, wherein the markers are selected from the group consisting of VCAN, NID1, PTX3, and THBS1 and wherein the expression level of the plurality of markers indicates or correlates with a diagnosis or recurrence of the cancer, the diagnostic kit or test device comprising a plurality of specific binding members, each of which selectively binds to a marker selected from the group consisting of VCAN, NID1, PTX3, and THBS1 and one or more reagents for detecting said specific binding members or one or more reagents for detecting and/or quantifying formation of a complex formed by said specific binding member and said marker.
Dependencies are inferred from the claim text.